Q2 2025

Filed Aug 14, 2025 · 10-Q · 45 days after period end · 0000950170-25-108438

Q2 2025 · 10-Q

Revenue—

Net Income

-$9.47M

N/M vs Q2 2024

EPS Diluted

-$0.86

N/M vs Q2 2024

Operating Income-$9,250,000N/M

Operating Cash Flowderived-$5,434,000N/M

Same quarter

Metric	Q2 2025	Q2 2024	Q2 2023	Q2 2022
Revenue	—	$0.00	$20.06M	$3.70M
Net Income	-$9.47M	-$4.17M	$3.98M	-$10.34M
EPS Diluted	-$0.86	-$2.47	$3.62	-$0.14

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR